Background Metformin is associated with low levels of vitamin B12 (VitB12) in patients with diabetes. The CCTG/MA.32 trial investigates the effects of metformin vs placebo on breast cancer (BC) outcomes in non-diabetic high-risk BC patients. We analyzed VitB12 at baseline and after 6 months of metformin (versus placebo) in the first 492 patients with paired blood samples.
Introduction
Metformin, a biguanide used in the treatment of type II diabetes, has emerged as a potential anti-cancer agent [1] . Multiple preclinical, epidemiological, and clinical studies have reported that metformin is associated with decreased cancer incidence and cancer-related mortality in diabetic patients [2] [3] [4] . Although definitive data are lacking, phase II and III trials have been launched to evaluate the effects of metformin on cancer outcomes. In breast cancer, Canadian Clinical Trial Group (CCTG) MA.32 is designed to assess the effectiveness of metformin vs placebo on invasive disease-free survival and other outcomes in 3649 non-diabetic women with early-stage breast cancer [5, 6] . Accrual to this trial has completed and follow-up is ongoing.
Recently, a meta-analysis by Chapman et al. [7] reported an association of low vitamin B12 plasma levels in patients with diabetes. A mean difference in vitamin B12 levels in metformin versus controls of 57 pmol/L after 6 weeks to 3 months of use in patients with type 2 diabetic was seen (fixed weighted mean difference, -0.57; 95% CI -35 to 79 pmol/L) [7] . A meta-analysis by Niafar et al. [8] identified an increased incidence of vitamin B12 deficiency in diabetic patients, defined as levels \150 pmol/L (OR = 2.45, 95% confidence interval, CI 1.74-3.44, p \ 0.0001) as well as lower mean vitamin B12 levels in those who received metformin (mean difference = -65.8, 95% CI -78.1 to -53.6 pmol/L, p \ 0.00001) versus control. Since metformin has been associated with decreased plasma levels of vitamin B12 in diabetic patients [7, 8] , a safety concern has been raised regarding its use in cancer patients.
Maintaining blinding of investigators to treatment allocation, we investigated the effects of metformin versus placebo on vitamin B12 status in the CCTG MA.32 trial. Vitamin B12 was assayed at baseline and after 6 months of metformin or placebo, in the first 492 patients with paired blood samples. Methylmalonic acid (MMA) and homocysteine (HC), often elevated in clinical vitamin B12 deficiency, were also analyzed in those patients with vitamin B12 levels below 222 pmol/L at either time point.
Materials and methods

Study design
The CCTG MA.32 Clinical Trial (Clinical Trials.gov identifier: NCT01101438 and EudraCT number: 2011-005230-18) [5] is a phase III trial that randomly assigned patients from Canada, the USA, the United Kingdom, and Switzerland to receive metformin 850 mg po bid or placebo po bid for 5 years. This study has enrolled 3649 non-diabetic women diagnosed with T1-3, N0-3, M0 breast cancer who had received standard surgical, chemotherapeutic, hormonal, biologic, and radiation treatment. Patients with T1c N0 breast cancer were eligible if they had at least one of the following risk factors: histologic grade III, lymphovascular invasion, negative estrogen (ER) and progesterone (PgR) receptors, HER2 positivity, Oncotype Recurrence Score C25, or Ki-67 over 14%. The exclusion criteria included fasting glucose C7.0 mmol/L, clinical diagnosis of diabetes, history of lactic acidosis, current use of diabetes medication, recurrence of breast cancer or prior breast cancer, excessive alcohol intake, or marked hepatic, kidney, or cardiac dysfunction.
This study was approved by the Adult Central Research Board ethics (US, NIH) and by boards of CCTG and participating centers, and is overseen by the CCTG Data Safety Monitoring Committee. In the core study, consenting women provided fasting blood (plasma, serum, whole blood), collected before initiation of study drug treatment and at 6 months (includes 4-week ramp-up of one caplet per day plus 20 weeks of full dose). The requirement for fasting blood reflects other goals, including investigation of metabolic factors. As part of correlative studies, the first 507 patients for whom the blood was available participated in the vitamin B12 substudy (CONSORT diagram, Fig. 1 ). Fifteen patients were excluded (12 from metformin arm and 3 from placebo arm, 8 were ineligible and 7 patients provided plasma samples at incorrect date) which led to 492 evaluable subjects. There were two patients with missing baseline vitamin B12 and three patients at 6 months in the final study population.
Measurements
Vitamin B12 was analyzed centrally in baseline and 6-month fasting plasma; levels \181 pmol/L were considered potentially deficient, 181-221 pmol/L borderline, and C222 pmol/L sufficient according to blood assays. MMA and HC (elevated in clinical vitamin B12 deficiency) were assayed in those with vitamin B12 levels \222 pmol/ L at either time point.
Fasting blood was collected, and plasma was frozen at -80°C, shipped on dry ice to ice to the central repository at CCTG in Kingston, Canada, and subsequently transported on dry ice to Mount Sinai Hospital (Toronto) at -80°C. Vitamin B12 (pmol/L) was quantified in one batch by a Roche E MODULAR ANALYTICS E170 (Elecsys module) immunoassay analyzers 170 ECLIA, ElectroChemiLuminescence ImmunoAssay (sensitivity \37 pmol/L and assay coefficient of variation \5%) in the Dr. Azar Azad laboratory at Mount Sinai Hospital (Toronto). Paired bloods (baseline and 6 months) were assayed in one batch.
Homocysteine and MMA were measured in patients with vitamin B12 \222 pmol/L at baseline or 6 months in reference laboratories with paired samples in the same batch using radioimmunoassay kits (Diazyme Enzymatic kit from Block Scientific for HC and GC-MSD for MMA) (assay coefficient of variation \8 and \10.43% for HC and MMA, respectively). HC testing was performed at the Department of Laboratory Medicine at St Michael's Hospital, Toronto, and MMA testing at the Laboratory Medicine Program, University Health Network, Toronto. Hemoglobin was measured at local centers.
Statistical analysis
Continuous variables were summarized with median and interquartile range (IQR), reflecting non-normal distributions. Correlations among continuous variables were calculated using Spearman rank correlation coefficient. Wilcoxon signed-rank test was used to compare the difference of continuous variables between metformin and placebo arms. Categorical variables were summarized with percentage of each group. Chi-square test was used to compare the differences of categorical variables between metformin and placebo arms. All analyses were conducted using SAS software (version 9.3).
Results
Population
Baseline characteristics of the study population, which are comparable to the whole patient population (data not shown), are summarized in Table 1 Baseline and change at six months measurements Table 2 . At 6 months, the median levels were lower -320 pmol/L (IQR 244, 419) in the metformin arm versus 380 pmol/L (IQR 286, 546) in the placebo arm (p = 0.0001). The median change from baseline to 6 months was -51 pmol/L (IQR 6, -182) in the metformin arm versus 0 (IQR -61, ?65) in the placebo arm, p \ 0.001 (see Table 3 ), and the mean percentage change of vitamin B12 from baseline to month 6 was -6.3% (standard deviation, SD 71, 65) and 7.52% (SD 51, 20) in the metformin and placebo arms, respectively. Fifteen patients (11 metformin and 4 placebo) had vitamin B12 \181 pmol/L at diagnosis (p = 0.3), and 18 patients (15 metformin and 3 placebo) had vitamin B12 \181 pmol/L at 6 months (p = 0.002). Figure 2 shows the scatter plots of vitamin B12 levels at baseline versus 6 months and at baseline versus change in the metformin and placebo arms. The 74 patients, who had vitamin B12 \222 pmol/L (45 in the metformin arm and 29 in the placebo arm) at baseline and/or 6 months, had MMA and HC measured. At baseline, MMA was normal in all these patients (median 0.16 lmol/L IQR 0.13, 0.24, Table 2 Table 2 ). The median change from baseline to 6 months was ?1 (range -4, 5.5) g/L and ?2 (range -3, 8) g/L in the metformin and placebo arms, respectively (p = 0.35) ( Table 3) . Changes in hemoglobin and vitamin B12 were not significantly correlated (Spearman correlation coefficient 0.05, p = 0.25).
Discussion
We have shown that, in the first 492 participants in the CCTG MA.32 trial, baseline vitamin B12 was in a normal range in the vast majority of subjects (97.3%). After 6 months of treatment, those patients who received metformin had significantly lower plasma levels of vitamin B12 compared to placebo. However, few patients in either arm had elevated MMA or HC (measured in those with vitamin B12 levels \222 pmol/L at either time point), suggesting that lower vitamin B12 levels were not indicative of clinical vitamin B12 deficiency. Hemoglobin was not significantly different at either time point and by treatment arm. Our results are consistent with the medical literature in patients without cancer. In the National Health and Nutrition Examination Survey (NHANES), 5.8% of diabetic patients using metformin compared with 2.4% of those with diabetes not using metformin had vitamin B12 levels B148 pmol/L (p = 0.0026) [9] and metformin use was associated with increased likelihood of vitamin B12 levels B148 pmol/L (adjusted odds ratio 2.92; 95% CI 1.26-6.78) [9] . Similarly, Jager et al. [10] reported a mean decrease in vitamin B12 concentration of -19% (95% CI -24 to -14%, p \ 0.001) in long-term (4.3 years) treatment with metformin compared to placebo in the Hyperinsulinemia: the Outcome of its Metabolic Effects (HOME) trial. They also reported a 5% increase in HC levels (95% CI, -10 to -0.4%; p \ 0.001) during the follow-up period [10] . In addition, in non-diabetic women with polycystic ovary syndrome taking metformin for 6 months, Greibe et al. [11] reported that metformin lowered vitamin B12 levels versus placebo (median 298, range 183-478, vs 346, 155-601, p = 0.003, respectively). Although treatment of diabetic patients with metformin is associated with a decline in plasma vitamin B12, it is unknown whether this results in clinical vitamin B12 deficiency, with neurological manifestations related to demyelination of spinal cord, cranial, peripheral nerves, or with megaloblastic anemia [12] . Although it has been suggested that metformin reduces vitamin B12 absorption, a recent study in rats showed that animals treated with metformin accumulate vitamin B12 in the liver which could also explain its lower plasma level [13] .
Additionally, because low plasma levels of vitamin B12 are not sufficient to diagnose the deficiency syndrome (which requires the neurologic and/or hematologic signs and symptoms outlined above), reductions in blood levels of vitamin B12, particularly in the absence of elevations in MMA or HC, have low diagnostic value [14] . Given that MMA and HC are elevated in the majority (98%) of patients with clinical vitamin B12 deficiency, it is recommended that these be measured in those patients with clinical symptoms [14] . MMA is more specific for vitamin B12 deficiency than HC which can be elevated in other conditions such as folate deficiency, classic homocystinuria, and renal failure [14] . In our study, only one patient (on metformin, 6-month measurement) had elevated MMA, which suggests that clinically relevant vitamin B12 deficiency may not be present in the majority of patients with low levels of vitamin B12, at least after 6 months of metformin.
Our study has limitations. We conducted measurements only at diagnosis and at 6 months. It is not known whether vitamin B12 varied between these times or after 6 months. Study measurements at 5 years will become available in future. Although standard adverse event reporting system was in place, data on clinical symptoms of vitamin B12 deficiency were not specifically collected. Additionally, no information about vitamin B12 supplementation is available. In future research, we will explore vitamin B12 levels, MMA, and HC after 5 years of metformin or placebo. 
Conclusion
In this substudy of the CCTG MA.32 clinical trial, we identified an increased frequency of biochemical, vitamin B12 deficiency after 6 months of metformin in breast cancer patients, but this did not appear to be associated with clinical vitamin B12 deficiency. These preliminary results suggest that metformin use in patients with earlystage breast cancer could be considered safe, although measurement of vitamin B12 on a regular basis, similar to recommendations in diabetic patients, may be prudent [15] . IQR interquartile range, n number of patients Fig. 2 Scatter plots of vitamin B12. Scatter plots of a vitamin B12 levels at baseline versus 6 months in the metformin arm, b vitamin B12 levels at baseline versus change at 6 months in the metformin arm, c vitamin B12 at baseline versus 6 months in the placebo arm, and d vitamin B12 levels at baseline versus change at 6 months in the placebo arm
